Thus, enhanced secretion of tumor-associated EVs can be related with tumor progression, suggesting a potential explanation concerning the negative prognostic value of circulating CD133+ EVs that we described in patients with advanced CRC [50]. This evidence concerns the gene PROM1 and neoplasm.